Myleran (Busulfan)

Busulfan belongs to the alkylating agent class. It binds to DNA, forming cross‑links that prevent DNA strands from separating during replication and transcription. This interference triggers cell death, especially in rapidly dividing cancerous and hematopoietic cells, providing its antineoplastic effect.

The specific dose of Myleran is individualized by the prescribing physician based on the patient’s disease, weight, organ function, and treatment protocol. Dosage calculations are performed by the treating oncologist or transplant specialist to ensure safety and efficacy.

Myleran is classified as Pregnancy Category D, indicating evidence of risk to the fetus. It should not be used by pregnant women, and breastfeeding is not recommended because the drug can be excreted in milk and may harm the infant.

To order Myleran, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Busulfan is often compared with cyclophosphamide or total body irradiation as conditioning agents. Compared with cyclophosphamide, Busulfan provides more predictable pharmacokinetics but requires careful monitoring for hepatic and pulmonary toxicity. Choice depends on the transplant protocol and patient-specific factors.

Myleran tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original container, protect from moisture and direct sunlight, and ensure the packaging remains sealed until use.

Myleran is administered orally as a tablet. The prescribing clinician determines the dosing schedule, which may involve single or divided doses over several days, depending on the treatment plan and patient tolerance.

Serious risks include hepatic veno‑occlusive disease, severe bone‑marrow suppression leading to pancytopenia, pulmonary fibrosis, and seizures. Patients should be monitored closely for signs of liver dysfunction, respiratory issues, and neurological symptoms throughout therapy.

Myleran is contraindicated in patients with known hypersensitivity to Busulfan, those who are pregnant, and individuals with severe hepatic impairment or uncontrolled infections. It should also be used with caution in patients with pre‑existing lung disease.